Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) EPS (Weighted Average and Diluted) (2016 - 2022)

Historic EPS (Weighted Average and Diluted) for RedHill Biopharma (RDHL) over the last 9 years, with Q2 2022 value amounting to $0.02.

  • RedHill Biopharma's EPS (Weighted Average and Diluted) fell 6666.67% to $0.02 in Q2 2022 from the same period last year, while for Jun 2022 it was $0.19, marking a year-over-year decrease of 2083.33%. This contributed to the annual value of $0.01 for FY2023, which is 10833.33% up from last year.
  • RedHill Biopharma's EPS (Weighted Average and Diluted) amounted to $0.02 in Q2 2022, which was down 6666.67% from $0.06 recorded in Q2 2021.
  • In the past 5 years, RedHill Biopharma's EPS (Weighted Average and Diluted) registered a high of $0.06 during Q2 2021, and its lowest value of $0.02 during Q2 2022.
  • For the 3-year period, RedHill Biopharma's EPS (Weighted Average and Diluted) averaged around $0.04, with its median value being $0.05 (2018).
  • In the last 5 years, RedHill Biopharma's EPS (Weighted Average and Diluted) crashed by 1666.67% in 2018 and then plummeted by 6666.67% in 2022.
  • Over the past 3 years, RedHill Biopharma's EPS (Weighted Average and Diluted) (Quarter) stood at $0.05 in 2018, then grew by 20.0% to $0.06 in 2021, then plummeted by 66.67% to $0.02 in 2022.
  • Its EPS (Weighted Average and Diluted) was $0.02 in Q2 2022, compared to $0.06 in Q2 2021 and $0.05 in Q2 2018.